[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhejiang University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":672},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,134,0,25,[9,49,71,106,138,169,191,211,232,254,278,307,333,355,383,413,437,468,495,523,548,574,596,625,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100652836","phase-2-16-hour-fasting-plus-serplulimab-and-capeox-as-neoadjuvant-therapy-in-pmmrmss-advanced-mid-to-low-rectal-cancer-100652836",false,"NCT07779694","16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR\u002FMSS Advanced Mid-to-Low Rectal Cancer","Neoadjuvant 16-Hour Fasting Combined With Serplulimab and CAPEOX for pMMR\u002FMSS Locally Advanced Mid-to-Low Rectal Cancer: A Prospective, Single-Arm, Phase II Trial.","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Male or female subjects ≧ 18 years ≦ 75 of age.\n3. Histological or cytological documentation of adenocarcinoma of the rectum.\n4. No previous any systemic anticancer therapy for rectal cancer disease.\n5. The primary rectal tumor is assessed as likely to be R0 resectable by a multidisciplinary colorectal cancer collaborative team, comprising at least 2 gastrointestinal surgeons and 1 radiologist.\n6. The lower margin of the tumor is less than 10cm from the anus verge.\n7. cT2N1-2M0, cT3N0-2M0, cT4N0-1M0 MSS with MRF(-) assessed by MRI.\n8. Primary tumor can be detected by CT or MRI.\n9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n10. Eligible tumor tissues were identified for MSI\u002FMMR assays.\n11. Hepatitis B Surface Antigen (HBsAg) (-).\n12. If HBsAg (+) , HBV-DNA must be less than 2500 copies\u002FmL or 500 IU\u002FmL to be enrolled.\n13. Patients with HCV antibody (-) or HCV-RNA negative can be enrolled. Aspartate aminotransferase (AST) must be ≤ 3 x ULN for the lab. If HCV-RNA is positive, patients with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) performed ≤3×ULN could be enrolled. Patients infected with both hepatitis B virus and hepatitis C virus should be excluded (positive for HBsAg or HBcAb and positive for HCV antibodies).\n\nExclusion Criteria:\n\n1. Patients with recurrent rectal cancer or a history of pelvic radiotherapy.\n2. Patients with a history of inflammatory bowel disease.\n3. Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease (HIV1 antibody, HIV2 antibody, HTLV1 antibody positive) should be excluded.\n4. Patients who are preparing for or have previously received an organ or bone marrow transplant.\n5. History of myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms in women) in the 6 months prior to enrollment (QTc interval calculated by Fridericia formula).\n6. According to New York College of Cardiology (NYHA) standards for Grade III-IV cardiac insufficiency or cardiac color ultrasound: left ventricular ejection fraction (LVEF) \\\u003C50%.Poor hypertension control (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg), a past hypertensive crisis or hypertensive encephalopathy.\n7. Poor hypertension control (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg), a past hypertensive crisis or hypertensive encephalopathy.\n8. Patients had undergone major surgery within 28 days prior to enrollment. Patients with tumor biopsy or lymph node dissection biopsy were admitted. Patients undergoing enterostomy due to intestinal obstruction were admitted.\n9. The patients had previously been treated with other antibodies\u002Fdrugs that target immune checkpoints, such as PD-1, PD-L1, and cytotoxic T lymphocyte-associated Antigen 4 (CTLA-4).\n10. Patients are participating in other clinical studies, or plan to start this study treatment less than 14 days from the end of the previous clinical study.\n11. Uncontrolled tumor-related pain.\n12. A known history of severe allergy to any monoclonal antibody.\n13. Known to be allergic or intolerance to any oxaliplatin and capecitabine ingredients.\n14. Pregnant or lactating women.\n15. The investigators determined that the patient had other factors that might have led to the early termination of the study.","ALL","18 Years","75 Years",{"count":21,"type":22},51,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Although standard neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) effectively reduces local recurrence, radiotherapy-related toxicities and surgical complications severely impair patients' quality of life, making a radiotherapy-free strategy urgently needed. However, chemotherapy alone yields a pathological complete response (pCR) rate of only 6.6%-15%, which is far from satisfactory.\n\nThe pMMR\u002FMSS subtype, accounting for 90% of rectal cancers, is \"immune-cold\" and shows almost no response to PD-1 monotherapy; nonetheless, chemotherapy can reshape the tumor immune microenvironment, and multiple studies have demonstrated that combining chemotherapy with PD-1 inhibitors (without radiotherapy) can elevate pCR rates to 26.8%-42.9%, yet further improvement remains desirable. A recent mechanistic study published in Cell Metabolism (2026) revealed that a single 16-hour fasting episode before treatment promotes isoleucine accumulation in the tumor microenvironment, which enhances CD8+T-cell cytotoxic function and reduces exhaustion through acetyl-CoA metabolism and epigenetic reprogramming, thereby significantly sensitizing PD-1 inhibitors-and this intervention is non-invasive, low-cost, and easily adoptable by patients.\n\nBased on the above evidence, we hypothesize that the neoadjuvant triple-combination regimen of \"16-hour fasting + chemotherapy + PD-1 inhibitor\" (radiotherapy-free) in pMMR\u002FMSS locally advanced mid-to-low rectal cancer may further increase pCR rates and tumor regression, offering a novel, highly effective, and low-toxicity therapeutic option for LARC patients.",[28,29,30],"pMMR\u002FMSS","Locally Advanced Rectal Carcinoma","Fasting, Intermittent",[32,33,34,35,36],"Rectal cancer","Serplulimab","CAPEOX","neoadjuvant therapy","16-hour fasting","NOT_YET_RECRUITING","2026-08-18",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":22},"2026-09-01",{"date":45,"type":22},"2029-12-31",{"name":47,"class":48},"Zhejiang University","OTHER",{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100652250","iparomlimab-and-tuvonralimab-combined-with-chemotherapy-and-bevacizumab-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-100652250","NCT07769853","Iparomlimab and Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","Iparomlimab and Tuvonralimab（QL-1706）Combined With Chemotherapy and Bevacizumab With or Without Radiotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer：A Multicenter, Single Arm Clinical Trial","IT-CABLE","Inclusion Criteria:\n\n* The patient voluntarily consents to participate in this study, demonstrates good compliance, is able to meet the trial requirements for observation and follow-up, and has signed the informed consent form;\n* Age between 18 and 75 years, inclusive, regardless of gender (at the time of signing the informed consent);\n* ECOG Performance Status (PS) score of 0 or 1;\n* Expected survival time ≥12 weeks;\n* Histologically confirmed diagnosis of mid- or upper-rectal adenocarcinoma, with the tumor located 5-12 cm from the anal verge;\n* Colonoscopic biopsy specimens assessed by the pathology department at the study center show pMMR by immunohistochemistry or MSS by genetic testing (PCR or NGS method);\n* Clinical staging of cT3-4N0M0 or cTxN+M0;\n* No prior anti-tumor therapy (including but not limited to radiotherapy, chemotherapy, targeted therapy, or immunotherapy);\n* At least one measurable lesion: the lesion must have one clearly measurable diameter (recorded as the longest diameter), with the minimum size defined as follows:\n* CT scan: ≥10 mm (CT slice thickness should not exceed 5 mm);\n* Malignant lymph nodes: must be pathologically enlarged and measurable, with a short-axis diameter of ≥15 mm on CT (recommended slice thickness ≤5 mm);\n* Major organ functions must be adequate, meeting the following criteria:\n\nHematology (without hematopoietic growth factors or blood transfusion within 7 days):\n\n1. Neutrophils ≥1.5 × 10⁹\u002FL\n2. Platelets ≥100 × 10⁹\u002FL\n3. Hemoglobin ≥90 g\u002FL\n\nBiochemistry:\n\ne) Total bilirubin ≤1.5 × ULN f) AST and ALT ≤2.5 × ULN g) Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n\nCoagulation:\n\nh) Coagulation function must meet the following conditions: INR ≤1.5 PTT or aPTT ≤1.5 × ULN\n\n\\- Subjects with reproductive potential must use appropriate contraceptive methods during the study and for 120 days after its completion. Female participants must have a negative serum pregnancy test within 7 days before enrollment and must not be breastfeeding.\n\nExclusion Criteria:\n\n* Clinical stage cT4b and low rectal cancer (tumor located less than 5 cm from the anal verge);\n* Prior rectal cancer surgery before enrollment, excluding stoma procedures;\n* History of malignancy, except for cured carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, or early-stage thyroid cancer;\n* Severe hypersensitivity or allergic reactions to humanized antibodies or fusion proteins in the past;\n* Pregnant or breastfeeding women, or women of childbearing potential who are not using contraception;\n* Diagnosed immunodeficiency or receiving systemic glucocorticoids or other immunosuppressive therapy within 14 days prior to the first dose of study treatment. Physiological doses of glucocorticoids (≤10 mg\u002Fday prednisone or equivalent) are allowed;\n* Active, known, or suspected autoimmune diseases (e.g., interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, etc.) are excluded. However, patients with type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, or skin conditions not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia), or conditions not expected to recur without an external trigger, may be enrolled;\n* Severe pre-existing cardiac conditions, including: congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, or severe valvular heart disease;\n* Hypertension that is poorly controlled with antihypertensive medication (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg). Patients are eligible if BP is well controlled with treatment. Patients with a history of hypertensive crisis or hypertensive encephalopathy are excluded;\n* Active hepatitis B (HBV DNA ≥2000 IU\u002Fml or 10⁴ copies\u002Fml) or hepatitis C (positive anti-HCV antibody and HCV-RNA above detection threshold);\n* Active tuberculosis (TB) infection, as determined by chest X-ray, sputum test, and clinical examination. Patients with a history of active TB infection within the past year are excluded even if treated. Those with TB infection more than a year ago are also excluded unless prior anti-TB treatment was appropriate in both duration and regimen;\n* Major surgery, incisional biopsy, or significant traumatic injury within 28 days prior to randomization;\n* Imaging indicates tumor invasion of major blood vessels, or in the investigator's opinion, the tumor is likely to invade major blood vessels during the study and pose a risk of fatal hemorrhage;\n* Any signs or history of bleeding disorders, regardless of severity; patients who had any bleeding event ≥ Grade 3 (CTCAE) within 4 weeks prior to randomization; patients with unhealed wounds, ulcers, or fractures;\n* Arterial or venous thrombotic events (e.g., stroke, transient ischemic attack, deep vein thrombosis, or pulmonary embolism) within the past 6 months;\n* Uncontrolled neurological or psychiatric disorders or mental illness leading to poor compliance or inability to report treatment response;\n* Any comorbid condition that, in the investigator's judgment, could seriously jeopardize patient safety or interfere with study completion;\n* Other conditions deemed inappropriate for enrollment by the investigator.",{"count":58,"type":22},56,[60],"NA","This study aims to observe and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab（QL-1706） combined with chemotherapy and bevacizumab ± radiotherapy as neoadjuvant therapy in patients with locally advanced rectal cancer, and to explore the value and implications of radiotherapy omission in this setting.",[63,64],"Locally Advanced Rectal Cancer (LARC)","5-12cm to Anal Verge","2026-08-16",{"date":38,"type":41},{"date":43,"type":22},{"date":69,"type":22},"2029-12-12",{"name":47,"class":48},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100652057","ai-assisted-feedback-for-learning-standardized-tuina-skills-100652057","NCT07767916","AI-Assisted Feedback for Learning Standardized Tuina Skills","Effects of Sensor- and Generative AI-Supported Personalized Feedback on the Acquisition of Standardized Tuina Skills Among Rehabilitation Trainees: A Randomized Controlled Trial","AI-TUINA","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Currently enrolled in or receiving training in rehabilitation medicine, physical therapy, rehabilitation therapy, or a related health profession.\n* Has not previously achieved the predefined competency standard for the standardized Tuina skill evaluated in this study.\n* Able to understand the study instructions and independently complete the training tasks and study questionnaires.\n* Able and willing to attend all scheduled training sessions and the four-week follow-up assessment.\n* Willing to participate voluntarily and provide written informed consent.\n\nExclusion Criteria:\n\n* Current acute injury, clinically significant pain, or functional limitation involving the hand, wrist, upper limb, shoulder, neck, or lower back that may interfere with repeated manual skill practice.\n* Previous systematic training in the same standardized Tuina technique with performance at or above the predefined competency standard.\n* Any medical, physical, cognitive, or psychological condition that, in the investigator's judgment, may make participation unsafe or prevent valid completion of the study procedures.\n* Unable to understand the study procedures or provide informed consent.\n* Direct involvement in the design, randomization, intervention delivery, outcome assessment, data management, or statistical analysis of this study.\n* Concurrent participation in another training study that may substantially affect performance of the standardized Tuina skill.",true,{"count":81,"type":22},81,[60],"The goal of this educational study is to determine whether personalized feedback generated using sensor data and generative artificial intelligence (AI) can improve the learning of standardized Tuina skills among rehabilitation trainees. Tuina is a form of manual therapy that requires learners to control the location, force, rhythm, and consistency of their hand movements.\n\nA total of 81 rehabilitation trainees will be randomly assigned to one of three training groups: AI-supported personalized feedback, sensor-based data feedback without AI-generated recommendations, or traditional instructor feedback. All groups will receive the same standardized demonstration, training tasks, practice duration, and number of practice sessions.\n\nThe main question is whether trainees receiving AI-supported personalized feedback achieve better retention of standardized Tuina skills four weeks after training. The researchers will also compare immediate skill performance, force and rhythm control, transfer of skills to a related task, learning efficiency, self-efficacy, cognitive load, satisfaction, and the safety and acceptability of AI-generated feedback.\n\nSkill performance will be assessed using a blinded Objective Structured Clinical Examination (OSCE) and objective sensor-based measurements. The study activities will be conducted using a mechanical simulation model and a pressure-sensing system, rather than on patients.",[85,86],"Medical Education","Clinical Skills",[88,89,90,91,92,93,94,95,96,97],"Artificial Intelligence","Generative Artificial Intelligence","Rehabilitation Education","Health Professions Education","Tuina","Manual Therapy Skills","Sensor-Based Feedback","Personalized Feedback","Deliberate Practice","Objective Structured Clinical Examination","2026-08-12",{"date":100,"type":41},"2026-08-17",{"date":102,"type":22},"2026-08-13",{"date":104,"type":22},"2028-08-01",{"name":47,"class":48},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100651848","dentate-targeted-temporal-interference-stimulation-for-post-stroke-dysphagia-100651848","NCT07766668","Dentate-Targeted Temporal Interference Stimulation for Post-Stroke Dysphagia","Individualized Transcranial Temporal Interference Stimulation Targeting the Dentato-Thalamo-Cortical Pathway for Post-Stroke Dysphagia: A Randomized, Double-Blind, Sham-Controlled Trial","DENTIS-PSD","Inclusion Criteria:\n\n* Age 18 to 80 years\n* First-ever unilateral supratentorial ischemic stroke confirmed by computed tomography or magnetic resonance imaging\n* Stroke onset 14 to 90 days before randomization\n* Oropharyngeal dysphagia confirmed by videofluoroscopic swallowing study, with a worst Penetration-Aspiration Scale score of 3 to 7 during prespecified standardized bolus trials\n* Medically stable and able to remain seated during stimulation and swallowing rehabilitation\n* Able to follow one-step commands, directly or with supported communication\n* Written informed consent provided by the participant or a legally authorized representative\n\nExclusion Criteria:\n\n* Brainstem or primary cerebellar stroke, bilateral cerebral infarction, previous symptomatic stroke, intracranial hemorrhage, or progressive neurological disease\n* Pre-stroke dysphagia, structural oropharyngeal disease, previous treatment for head and neck cancer, or another condition that independently explains dysphagia\n* Tracheostomy, current mechanical ventilation, uncontrolled pneumonia, severe hypoxemia, or hemodynamic instability\n* History of epilepsy, seizure after the index stroke, unexplained loss of consciousness, or current use of medication considered to confer an unacceptable seizure risk\n* Intracranial metallic material, implanted electronic device, cochlear implant, or another contraindication to transcranial temporal interference stimulation, magnetic resonance imaging, or transcranial magnetic stimulation\n* Severe cognitive, behavioral, or language impairment that prevents participation despite supported communication\n* Pregnancy or breastfeeding\n* Major scalp disease at the planned electrode sites\n* Participation in another interventional clinical trial\n* Any other condition considered unsafe or unsuitable by the investigator","80 Years",{"count":116,"type":22},88,[60],"The goal of this clinical trial is to learn whether individualized transcranial temporal interference stimulation can improve swallowing in adults with swallowing difficulties after an ischemic stroke. It will also evaluate the safety and tolerability of this stimulation. The main questions it aims to answer are:\n\n* Does active temporal interference stimulation combined with swallowing rehabilitation improve swallowing safety more than sham stimulation combined with the same rehabilitation?\n* What side effects or medical problems occur during and after the stimulation?\n\nResearchers will compare active stimulation with sham stimulation, which uses the same equipment but does not deliver sustained therapeutic stimulation.\n\nParticipants will:\n\n* Receive active or sham stimulation for 30 minutes per session, 5 days per week for 2 weeks\n* Receive the same task-specific swallowing rehabilitation after each stimulation session\n* Undergo swallowing assessments, brain imaging, and neurophysiological testing\n* Attend follow-up assessments 4 and 12 weeks after treatment",[120,121],"Deglutition Disorders","Ischemic Stroke",[123,124,125,126,127,128,129],"stroke","dysphagia","temporal interference stimulation","cerebellar dentate nucleus","swallowing rehabilitation","neuroplasticity","randomized controlled trial","2026-08-09",{"date":132,"type":41},"2026-08-14",{"date":43,"type":22},{"date":135,"type":22},"2030-03-01",{"name":47,"class":48},1,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":156,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":137},"100613185","evaluation-of-diaphragmatic-function-after-interscalene-block-with-liposomal-bupivacaine-100613185","NCT07263295","Evaluation of Diaphragmatic Function After Interscalene Block With Liposomal Bupivacaine","Evaluation of Diaphragmatic Function After Interscalene Brachial Plexus Block With Liposomal Bupivacaine: A Cohort Study","Inclusion Criteria:\n\n* Patients undergoing upper limb surgery scheduled for interscalene brachial plexus block\n* Aged ≥ 18 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n\nExclusion Criteria:\n\n* Known allergy or intolerance to amide local anesthetics\n* Nerve injury in the upper limb on the surgical side\n* Coagulopathy\n* Used opioid medications continuously for more than 3 weeks before surgery\n* History of pulmonary disease and a pulse oxygen saturation (SpO₂) \\\u003C 95% (measured after 5 minutes of rest at room temperature without oxygen supplementation, using a transcutaneous pulse oximeter)\n* Refuse to participate or are deemed unsuitable for this trial by the researchers\n\nWithdrawal Criteria:\n\n* Patients voluntarily withdrew their informed consent\n* Surgery was canceled or the anesthesia method was changed due to surgical factors before interscalene brachial plexus block",{"count":146,"type":22},120,[60],"The study aims to evaluation the effects of Liposomal Bupivacaine on diaphragmatic function in patients undergoing upper limb surgery who receive Interscalene Brachial Plexus Block. A total of 120 eligible patients will be enrolled and divided into two groups: Group A will receive 20ml of 0.5% Hydrochloride Bupivacaine , while Group B will receive 10ml of 0.5% Hydrochloride Bupivacaine plus 10ml of Liposomal Bupivacaine. Assessments of diaphragmatic function, pulmonary function, and pain intensity will be performed before the block and at different time points after the block, with follow-up for adverse events. The study is scheduled to run from September 2025 to September 2026, with strict adherence to privacy protection and ethical guidelines.",[150,151,152,153,154,155],"Diaphragmatic Function","Metacarpal Fracture","Radius Fracture","Peripheral Nerve Neurolysis","Chronic Ulcer","Upper Extremity Ligament Injury",[157,158,159],"Interscalene brachial plexus block","Liposomal Bupivacaine","Hemidiaphragmatic paralysis","RECRUITING","2026-07-30",{"date":163,"type":41},"2026-08-03",{"date":165,"type":41},"2025-12-05",{"date":167,"type":22},"2026-08-25",{"name":47,"class":48},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":137},"100649600","phase-1-a-pan-ras-inhibitor-in-combination-with-anti-tumor-therapy-in-participants-with-advanced-pancreatic-cancer-100649600","NCT07736612","A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","A Phase Ib\u002FII Study of the Safety, Tolerability, and Efficacy of a Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histopathologically confirmed locally advanced or metastatic pancreatic adenocarcinoma (originating from pancreatic ductal epithelium) that is not amenable to curative therapy.\n* RAS mutation or amplification detected in tumor tissue or blood (by RAS testing).\n* Prior anti-tumor therapy:\n\n  1. For cohort HRS-2329-A: at least one line of standard systemic therapy in the advanced setting;\n  2. For cohorts HRS-2329-B and HRS-2329-C: at most one line of standard systemic therapy in the advanced setting.\n* At least one measurable lesion according to RECIST version 1.1 criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n* Life expectancy ≥ 3 months.\n* Adequate function of vital organs.\n* Use of appropriate contraceptive methods during the study period, and so forth.\n* Voluntary participation in this study with signed informed consent, good compliance, and willingness to cooperate with follow-up assessments.\n\nExclusion Criteria:\n\n* Prior treatment with drugs similar to the investigational product.\n* Known presence of central nervous system (CNS) metastases.\n* Acute or chronic pancreatitis requiring clinical intervention.\n* Gastrointestinal disorders that may affect drug administration\u002Fabsorption, including but not limited to dysphagia, malabsorption syndrome, refractory nausea, vomiting, or diarrhea, Crohn's disease, and ulcerative colitis.\n* Gastrointestinal obstruction, or signs\u002Fsymptoms of gastrointestinal obstruction; however, patients who have undergone surgical intervention with complete resolution of the obstruction may be considered for screening.\n* Concurrent biliary obstruction with risk of biliary tract infection (patients with treatable biliary obstruction may be enrolled if adequate biliary drainage is achieved and the risk of biliary infection is resolved after treatment).\n* Third-space fluid collections (e.g., massive pleural effusion, ascites) that cannot be stabilised (i.e., no intervention required after drainage removal) within 2 weeks prior to enrolment; patients with only a small amount of fluid detected by imaging and without clinical symptoms may be enrolled.\n* Severe infection within 4 weeks prior to enrolment, such as severe pneumonia, bacteraemia, or infectious complications requiring hospitalisation; unexplained fever \\>38.5°C within 2 weeks prior to enrolment ; signs\u002Fsymptoms of infection requiring intravenous antibiotic therapy within 2 weeks prior to enrolment.\n* Severe cardiovascular or cerebrovascular diseases.\n* Known or suspected interstitial lung disease (isolated imaging findings of interstitial changes are not excluded).\n* History of definite neurological or psychiatric disorders, including epilepsy and dementia.\n* Non-healing wounds (severe, non-healing, or dehiscent), or unhealed fractures.\n* Adverse events from prior therapy not recovered to NCI-CTCAE Grade ≤1 at enrolment .\n* History of malignancies other than the primary tumour within 5 years prior to enrolment, with the exception of malignancies with low risk of metastasis and death, such as adequately treated carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin.\n* Active hepatitis B infection.\n* For Cohort C, conditions that are unsuitable for immunotherapy.\n* Known allergy to any component of any of the study drugs to be administered.\n* Any other condition that, in the investigator's judgement, may affect the study results or result in premature termination of the study.",{"count":177,"type":22},80,[179,25],"PHASE1","This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.",[182,183],"Pancreatic Cancer","RAS Mutations or Amplifications","2026-07-27",{"date":161,"type":41},{"date":187,"type":22},"2026-08-15",{"date":189,"type":22},"2029-12-30",{"name":47,"class":48},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":137},"100649071","phase-2-precision-integrated-strategies-and-efficacy-evaluation-for-biliary-tract-cancers-an-umbrella-platform-study-100649071","NCT07729917","Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study","Inclusion Criteria:\n\n* The patient voluntarily joins this study and signs the informed consent form.\n* Age: ≥18 years, male or female.\n* Histologically or cytologically confirmed advanced biliary tract malignancies, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer.\n* No prior systemic therapy for advanced BTC (biliary tract cancer).\n* At least one measurable lesion as per RECIST v1.1 (spiral CT scan long diameter ≥10 mm or short diameter of enlarged lymph node ≥15 mm; lesions previously treated with local therapy may be considered target lesions only after documented progression according to RECIST v1.1).\n* ECOG performance status: 0-1.\n* Expected survival ≥12 weeks.\n* Adequate major organ function.\n* Female subjects of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days before the first dose, must not be breastfeeding, and must voluntarily agree to use effective contraceptive measures during the study period and for 6 months after the last dose of chemotherapy. For male subjects with a female partner of childbearing potential, they must be surgically sterile or agree to use effective contraceptive measures during the study period and for 3 months after the last dose of chemotherapy; sperm donation is not allowed during the study.\n* Subjects are expected to have good compliance and be able to follow the protocol requirements for efficacy and adverse event follow-up.\n\nExclusion Criteria:\n\n* Has another active malignancy other than BTC within 5 years or concurrently.\n* Has poorly controlled cardiac clinical symptoms or diseases.\n* Has hypertension that cannot be reduced to normal range with antihypertensive medication; has a history of hypertensive crisis or hypertensive encephalopathy.\n* Any clinically significant gastrointestinal disorders, including bleeding, inflammation, obstruction, or diarrhea \\> grade 2.\n* Has experienced thrombotic or embolic events within 6 months before the start of study treatment.\n* Use of strong CYP3A4\u002FCYP2C19 inducers (including rifampin and its analogues, and St. John's Wort) or strong CYP3A4\u002FCYP2C19 inhibitors and\u002For strong UGT1A inhibitors within 14 days prior to signing the informed consent form.\n* Has uncontrolled infection at screening.\n* Patients with congenital or acquired immunodeficiency.\n* Has a history of brain metastases or has brain metastases.\n* Women who are pregnant or plan to become pregnant during the study treatment period.\n* Other patients deemed unsuitable for inclusion by the treating physician.",{"count":198,"type":22},240,[25],"This study is a prospective, multicenter, open-label, umbrella phase II clinical trial. Based on different multigene expression profiling subtypes and potential molecular characteristics of various pathways, 8 treatment arms and 13 treatment groups are preliminarily designed. After successful screening, investigators will assign eligible subjects to a treatment group based on the patient's genetic test report (if available) and performance status. For subjects without a genetic test report, they will be allocated to Arm H to receive immunotherapy combined with chemotherapy or other regimens.",[202,203],"Bile Duct Carcinoma","Cholangiocarcinoma",{"date":205,"type":41},"2026-07-28",{"date":207,"type":22},"2026-08-10",{"date":209,"type":22},"2030-12-31",{"name":47,"class":48},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":137},"100611909","phase-1-ksv01-injection-as-the-therapy-for-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia-100611909","NCT07246707","KSV01 Injection as the Therapy for Relapsed\u002FRefractory B-Cell Acute Lymphoblastic Leukemia","A Phase I Clinical Study on the Safety, Tolerability, and Efficacy of KSV01 Injection in Patients With Relapsed\u002FRefractory B-Cell Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n1. Voluntary participation and provision of written informed consent by the patient or their legally authorized representative.\n2. Aged 18 to 80 years (inclusive), any gender.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.\n4. Life expectancy \\> 3 months.\n5. Diagnosis of B-cell Acute Lymphoblastic Leukemia (B-ALL) according to the 2016 WHO classification, with relapsed\u002Frefractory disease defined by meeting at least one of the following criteria:\n\n   * Relapse within 12 months of achieving first remission with standard therapy.\n   * Primary refractory disease: failure to achieve Complete Remission (CR) after two or more cycles of standard chemotherapy.\n   * Relapsed disease after two or more instances of CR.\n   * Relapsed or refractory disease following autologous or allogeneic Hematopoietic Stem Cell Transplantation (HSCT).\n6. Documented CD19-positive leukemia cells in bone marrow or peripheral blood within 1 month prior to screening.\n7. Morphological disease in the bone marrow (blasts ≥5%).\n8. For patients with Philadelphia chromosome-positive ALL (Ph+ ALL): must be refractory or intolerant to at least two Tyrosine Kinase Inhibitors (TKIs), including at least one second-generation TKI. Patients with a T315I mutation are exempt from prior TKI salvage therapy.\n9. Absolute Lymphocyte Count (ALC) ≥ 100\u002FμL.\n10. Adequate organ function as defined by:\n\n    1. Hepatic: Alanine aminotransferase (ALT) ≤ 3 × Upper Limit of Normal (ULN); Aspartate aminotransferase (AST) ≤ 3 × ULN; Total bilirubin ≤ 2 × ULN (or ≤ 3 × ULN with a diagnosis of Gilbert's syndrome, with direct bilirubin ≤ 1.5 × ULN).\n    2. Renal: Creatinine clearance (calculated by Cockcroft-Gault formula) ≥ 60 mL\u002Fmin.\n    3. Pulmonary: Oxygen saturation (SaO2) ≥ 92% on room air, and no active pulmonary infection.\n    4. Cardiac: Left Ventricular Ejection Fraction (LVEF) ≥ 40% by echocardiography; absence of significant pericardial effusion; no clinically significant electrocardiogram (ECG) abnormalities.\n11. For women of childbearing potential: negative urine or serum pregnancy test at screening, and agreement to use effective contraception for at least 1 year post-infusion. Male subjects with partners of childbearing potential must agree to use effective barrier contraception for at least 1 year post-infusion.\n12. For subjects with prior blinatumomab (CD3-CD19 bispecific T-cell engager) therapy: CD19 tumor expression on blasts (from bone marrow or peripheral blood) must be documented after the most recent cycle of blinatumomab. If CD19 expression is quantified, the percentage of CD19-positive blasts must be ≥90%.\n\nExclusion Criteria:\n\n1. Diagnosis of Burkitt's leukemia\u002Flymphoma according to WHO 2016, or chronic myeloid leukemia in accelerated or blast phase.\n2. History of another primary malignancy that has not been in continuous remission for at least 2 years. Exceptions to the 2-year limit include: non-melanoma skin cancer, curatively treated Stage I solid tumor with low risk of recurrence, cured carcinoma in situ of the cervix (biopsy-confirmed) or squamous intraepithelial lesion on Pap smear, and cured localized prostate cancer.\n3. Uncontrolled active infection within 4 weeks prior to enrollment.\n4. Active hepatitis B or hepatitis C virus infection.\n5. HIV infection.\n6. Positive for Treponema pallidum(syphilis).\n7. Severe active autoimmune disease or immunodeficiency, with the exception of well-controlled Type I diabetes and thyroid disorders.\n8. History of severe allergy or hypersensitivity to macromolecular biological agents (e.g., antibodies, cytokines).\n9. Participation in another interventional clinical trial within 4 weeks prior to enrollment.\n10. History of clinically significant central nervous system (CNS) disorders, including but not limited to epilepsy, paresis, aphasia, stroke, severe head injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome.\n11. Central Nervous System (CNS) involvement:\n\n    * Presence of CNS 3 disease, defined as detectable blasts in the cerebrospinal fluid (CSF) with ≥5 WBCs\u002Fmm³, with or without neurological symptoms.\n    * Presence of CNS 2 disease, defined as detectable blasts in the CSF with \\\u003C5 WBCs\u002Fmm³ AND the presence of neurological symptoms.\n\n    Note: Subjects with CNS 1 status (no detectable leukemic blasts in CSF) and subjects with CNS 2 status without significant clinical neurological abnormalities are eligible.\n    * History or presence of any CNS disorder, such as seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, any autoimmune disorder involving the CNS, posterior reversible encephalopathy syndrome, or cerebral edema.\n12. History of concomitant genetic syndromes associated with bone marrow failure, such as Fanconi anemia, Kostmann syndrome (severe congenital neutropenia), Shwachman-Diamond syndrome.\n13. History of any of the following cardiovascular conditions within the past 6 months: New York Heart Association (NYHA) Class III or IV heart failure, cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease.\n14. Active psychiatric illness.\n15. History of drug abuse\u002Faddiction.\n16. Use of the following medications or therapies:\n\n    1. Salvage systemic therapy (including chemotherapy, TKIs for Ph+ ALL, and blinatumomab) within 1 week or 5 half-lives (whichever is shorter) prior to study drug infusion.\n\n       Note:\n\n       TKIs and hydroxyurea must be discontinued at least 72 hours prior to study drug infusion.\\* 6-mercaptopurine, 6-thioguanine, methotrexate (standard dose), cytarabine (standard dose), vincristine, and asparaginase must be discontinued at least 1 week prior.\\* Intrathecal chemotherapy for CNS prophylaxis must be discontinued at least 1 week prior.\\* PEG-asparaginase must be discontinued at least 4 weeks prior.\\*\n    2. Prior anti-CD19 therapy other than blinatumomab.\n    3. History of Grade 4 neurological toxicity (per CTCAE v6.0) or Grade 4 CRS (per Lee 2014 criteria) during prior blinatumomab treatment.\n    4. Prior treatment with alemtuzumab within 6 months, or with clofarabine or cladribine within 3 months prior to study drug infusion.\n    5. Systemic treatment for Graft-versus-Host Disease (e.g., calcineurin inhibitors, methotrexate, mycophenolate mofetil, sirolimus, thalidomide) or immunosuppressive antibody therapy (e.g., anti-CD20, anti-TNF, anti-IL-6, or anti-IL-6R antibodies) within 4 weeks prior to enrollment.\n    6. Any prior systemic therapy with inhibitory\u002Fstimulatory immune checkpoint molecules (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists). A washout period of at least 3 half-lives from the last dose is required before enrollment.\n    7. Radiotherapy: Non-CNS directed radiotherapy within 2 weeks or CNS-directed radiotherapy within 8 weeks prior to study drug infusion.\n    8. Corticosteroids: Therapeutic doses of corticosteroids (defined as prednisone equivalent \\>20 mg\u002Fday) within 72 hours prior to study drug infusion. Physiologic replacement doses, and topical or inhaled steroids are permitted.\n    9. Prior gene therapy.\n17. Acute Graft-versus-Host Disease (GVHD) of Grade II to IV per Glucksberg criteria, or overall grade B-D per the IBMTR Severity Index; OR acute or chronic GVHD requiring systemic therapy within 4 weeks prior to enrollment.\n18. Administration of a live vaccine within 4 weeks prior to enrollment.\n19. Pregnancy or lactation.\n20. Any condition that, in the investigator's judgment, may compromise the subject's ability to complete all required study visits and procedures (including follow-up), or comply with the study requirements.",{"count":219,"type":22},30,[179],"This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 injection for patients with relapsed\u002Frefractory B-Cell acute lymphoblastic leukemia (r\u002Fr B-ALL).",[223],"B-ALL","2026-07-16",{"date":226,"type":41},"2026-07-17",{"date":228,"type":41},"2026-01-02",{"date":230,"type":22},"2028-06",{"name":47,"class":48},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":253,"locationsCount":137},"100582171","leaf-liver-tumor-detection-and-classification-ai-100582171","NCT06859840","LEAF (Liver Tumor dEtection And classiFication AI)","Clinical Research on the Use of Non-contrast CT Combined With AI for Early Screening for Liver Malignancy","LEAF","Inclusion Criteria:\n\nAge range 18 years and above;\n\nUnderwent non-contrast chest or abdominal CT examination with liver coverage;\n\nPatients with an established diagnosis of cirrhosis;\n\nPatients with an established diagnosis of extrahepatic cancer.\n\nExclusion criteria:\n\nPatients who have been diagnosed with malignant liver tumor;\n\nPatients who underwent liver transplantation;\n\nLow quality image, severe artifacts and noise.","90 Years",{"count":242,"type":22},2500,[60],"This study aims to assess the feasibility of leveraging non-contrast CT and artificial intelligence to detect liver cancer in consecutive real-world patients. To this end, we deploy LEAF in a prospective real-world clinical setting for real-time monitoring, with a particular focus on flagging cases with liver cancer that may be missed by routine clinical workflow.",[246],"Liver Malignancy",[88,248],"liver malignancy",{"date":226,"type":41},{"date":226,"type":22},{"date":252,"type":22},"2026-11-10",{"name":47,"class":48},{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":137},"100642345","efficacy-and-safety-of-the-visual-bronchial-blocker-for-lung-isolation-surgery-100642345","NCT07644104","Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation Surgery","Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation Surgery: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* ASA physical status I-III\n* Scheduled for elective thoracic surgery (pulmonary, esophageal, or mediastinal procedures) requiring one-lung ventilation and lung isolation\n* Able to understand and sign the informed consent form\n\nExclusion Criteria:\n\n* Anatomical abnormalities of the tracheobronchial tree, including anomalous right upper lobe bronchial origin, severe airway stenosis, or distortion\n* Planned bronchial sleeve resection or carinal surgery\n* Empyema, bronchopleural fistula, or severe pleural adhesions affecting bronchial anatomy\n* Previous thoracic surgery that altered bronchial anatomy\n* Severe cardiopulmonary dysfunction with a metabolic equivalent (MET) \\\u003C 4\n* Severe psychiatric disorders or inability to cooperate with anesthesia procedures\n* Current participation in another interventional clinical trial\n* Contraindications to bronchial blocker placement (e.g., known allergy to materials used, high risk of airway trauma)",{"count":262,"type":22},652,[60],"This multicenter, prospective, randomized, controlled clinical trial is initiated by the First Affiliated Hospital of Zhejiang University School of Medicine, with participation from Peking Union Medical College Hospital, the Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University Cancer Hospital, and Shanxi Bethune Hospital. The study aims to compare the first-attempt placement success rate between visual bronchial blockers (VBB, test group) and conventional bronchial blockers (CBB, control group) during anesthesia for thoracic surgery, and to evaluate operational efficiency, lung isolation quality, and safety profiles.\n\nA total of 652 patients aged ≥18 years with ASA physical status I-III, scheduled for elective pulmonary, esophageal, or mediastinal surgery requiring lung isolation, will be enrolled in a 1:1 ratio (326 per group), with a 10% anticipated dropout rate. Key exclusion criteria include anomalous right upper lobe bronchial origin, severe airway anatomical abnormalities, bronchial sleeve resection, empyema, bronchopleural fistula, previous thoracic surgery altering bronchial anatomy, severe cardiopulmonary dysfunction (metabolic equivalent \\\u003C4), severe psychiatric disorders, and concurrent participation in other clinical trials.\n\nFollowing standardized anesthesia induction with rocuronium (2-3 × ED95), patients undergo tracheal intubation using a video laryngoscope. In the CBB group, placement is guided by blind probing and auscultation, with confirmation via fiberoptic bronchoscopy (FOB). In the VBB group, placement is performed under direct vision using the integrated camera, with FOB rescue allowed only if visualization fails (rescue cases are counted as failures). Placement success is defined as the cuff located in the ipsilateral main bronchus with the proximal cuff edge immediately below the carina.\n\nPrimary endpoint: First-attempt placement success rate. Secondary endpoints: Time to successful first placement, lung collapse grade (Likert 3-point scale), cumulative number and duration of FOB use, intraoperative blocker displacement, hypoxemia (SpO₂ \\\u003C90% or \\\u003C85% for ≥5 seconds), airway injury, hemodynamic changes, postoperative sore throat, hoarseness, hospital length of stay, ICU admission rate, postoperative pulmonary complications, and 30-day all-cause mortality. Operator and surgeon satisfaction will be rated on a 0-10 scale.\n\nRandomization is centralized, stratified by center, using variable block sizes (4, 6, or 8) to ensure allocation concealment. Outcome assessors and patients are blinded to group assignment, while operators are not. An independent Endpoint Adjudication Committee will review imaging data for blinded verification.\n\nStatistical analysis will be performed using SPSS 27.0 and R software. Baseline characteristics will be compared using independent samples t-test, Mann-Whitney U test, chi-square test, or Fisher's exact test as appropriate. The primary endpoint (binary variable) will be analyzed using generalized linear mixed models (GLMM) with center as a random effect and logistic regression as a sensitivity analysis. A two-sided P\\\u003C0.05 is considered statistically significant. Full Analysis Set (intention-to-treat), Per-Protocol Set, and Safety Set will be defined for efficacy and safety evaluations.\n\nThe trial timeline includes registration and training (June 2026 - August 2026), patient recruitment and data collection (September 2026 - September 2027), and data analysis, manuscript preparation, and publication (October 2027 - Dec 2028). Adverse events will be monitored, documented, and reported in accordance with CTCAE v5.0; serious adverse events will be reported to the ethics committee within 24 hours.\n\nThis study is the first randomized controlled trial evaluating a visual bronchial blocker worldwide. The investigators hypothesize that VBB improves first-attempt placement success, shortens positioning time, reduces FOB reliance, enhances lung collapse quality, decreases intraoperative displacement and hypoxemia, and lowers airway injury and postoperative complications. The results will provide high-level evidence for the clinical application of VBB in thoracic anesthesia and promote the visualization and standardization of one-lung ventilation techniques.",[266,267,268,269],"Thoracic Surgery With One-lung Ventilation","Lung Isolation","Bronchial Blockage","Anesthesia","2026-06-11",{"date":272,"type":41},"2026-06-12",{"date":274,"type":22},"2026-08-01",{"date":276,"type":22},"2027-12-31",{"name":47,"class":48},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":294,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":304,"leadSponsor":305,"locationsCount":306},"100642549","supraglottic-oxygenation-via-oral-transtracheal-catheter-for-reducing-the-incidence-of-hypoxemia-during-ercp-under-sedation-100642549","NCT07637721","Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation","Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation：a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age≥18years\n* The ASA classification ranges from I to III\n* Patients have signed the informed consent form\n* Patients scheduled to undergo sedated ERCP examination procedure\n\nExclusion Criteria:\n\n* Severe cardiac dysfunction (\\\u003C4 METs);\n* Diagnosed chronic obstructive pulmonary disease (COPD) or other acute\u002Fchronic pulmonary diseases requiring long-term\u002Fintermittent oxygen therapy;\n* Upper respiratory tract infections including oral, nasal or pharyngeal infections;\n* Fever (core temperature \\>37.5°C);\n* Confirmed pregnancy or current breastfeeding;\n* Hypersensitivity to sedative drugs such as propofol;\n* Current participation in other clinical trials;",{"count":286,"type":22},410,[60],"Endoscopic retrograde cholangiopancreatography (ERCP) is commonly used for the diagnosis and treatment of pancreatobiliary diseases. While Monitored Anesthesia Care (MAC) enhances the efficiency of ERCP, deep sedation introduces significant airway risks, particularly hypoxemia resulting from sedative-induced upper airway collapse. With reported hypoxemia rates ranging from 10% to 69%, and the potential for severe complications such as myocardial ischemia and neurological damage, effective airway management is paramount. Supraglottic oxygenation via oral transtracheal catheter provides a viable method for relieving obstruction and enabling positive pressure ventilation, serving as a less invasive alternative to tracheal intubation. Despite its proven utility in other settings, this technique has not yet been evaluated in the context of deeply sedated ERCP.",[290,291,292,293],"Choledocholithiasis With Cholecystitis With Obstruction","Obstructive Jaundice","Pancreatitis","Cholelithiasis",[295,296,297,298,299],"ERCP","Monitored Anesthesia Care","deep sedation","hypoxemia","The Supraglottic Oxygenation Via Oral Transtracheal Catheter","2026-06-09",{"date":302,"type":41},"2026-06-10",{"date":272,"type":22},{"date":276,"type":22},{"name":47,"class":48},3,{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":137},"100484853","phase-3-transarterial-neoadjuvant-chemotherapy-vstraditional-intravenous-chemotherapy-for-locally-advanced-gastric-cancer-with-soxpd-1-100484853","NCT05593458","Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1","A Multicenter, Randomized, Controlled Study of S-1 Combined With Oxaliplatin by Arterial Infusion Plus PD-1 Antibody Versus Conventional SOX Chemotherapy Plus PD-1 Antibody for Locally Advanced Gastric Cancer","TACTIC","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group(ECOG) score 0-1\n* Ambulatory males or females, aged 18-75 years\n* Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (Siewert type II or III)\n* Locally advanced gastric carcinoma (cT3N2-3M0, cT4aN1-3M0, cT4bNanyM0, American Joint Committee on Cancer (AJCC) TNM staging system 8th edition)\n* Life expectancy more than 3 months\n* Give written informed consent, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.\n* Normal hepatic, renal, and bone marrow function (ALT\u002FAST\\\u003C2.5 fold of upper limit value;Tbil\\\u003C1.5mg\u002Fdl, Cr\\\u003C1.5 fold of upper limit value; White Blood Cell count≥3 × 10\\^9\u002FL, ANC ≥ 1.5 × 10\\^9\u002FL,PLT≥ 80 × 10\\^9\u002FL,Hb ≥ 90 g\u002FL).\n\nExclusion Criteria:\n\n* Patients can not bear surgical procedure.\n* Pregnant or lactating women.\n* HER2 overexpression(+++) confirmed by immunohistochemistry.\n* Previous cytotoxic chemotherapy, radiotherapy or immunotherapy.\n* History of another malignancy within the last five years.\n* History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the Investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.\n* Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 12 months.\n* History of dysphagia, complete or partial gastrointestinal obstruction, active gastrointestinal bleeding and gastrointestinal perforation;\n* Organ allografts requiring immunosuppressive therapy.\n* Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.\n* Moderate or severe renal impairment: serum creatinine \\> 1.5 x upper limit of normal (ULN).\n* Hypersensitivity to any drug of the study regimen.\n* With abdominal cavity implantation metastasis or distant metastasis.\n* Unwilling or unable to comply with the protocol for the duration of the study.",{"count":316,"type":22},190,[318],"PHASE3","SOX regimen, consisting of oral S-1 and intravenous oxaliplatin, is the preferred regimen for perioperative chemotherapy for gastric cancer. The goal of this clinical trial is to compare the efficacy and safety between S-1 combined with oxaliplatin by arterial infusion, as neoadjuvant chemotherapy, and conventional SOX regimen, in locally advanced gastric cancer. The main question it aims to answer is: whether arterially infused oxaliplatin plus S-1 has the potential to be a better neoadjuvant option for patients with locally advanced gastric cancer.\n\nParticipants will be randomised, and receive:\n\n* 3 cycles of conventional SOX chemotherapy plus PD-1 antibody or arterial infused oxaliplatin plus S-1 and PD-1 antibody, as neoadjuvant chemotherapy;\n* Adequate gastric resection along with D2 lymph node dissection;\n* 3 cycles adjuvant chemotherapy using SOX regimen plus PD-1 antibody.\n* Administration of S-1 regularly till 1 year after surgery.\n\nResearchers will compare Major pathological response rate (MPR) ，pathologic complete response rate（pCR）,the 2-year overall survival (OS) rates, 2-year disease free survival (DFS), R0 resection rates, and adverse events, to see if the modified perioperative chemotherapy improve the prognosis of patients with locally advanced gastric cancer.",[321],"Locally Advanced Gastric Carcinoma",[323,324,35,325],"gastric cancer","arterial infusion","immunotherapy","2026-06-08",{"date":270,"type":41},{"date":329,"type":41},"2023-03-01",{"date":331,"type":22},"2026-12",{"name":47,"class":48},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":354},"100575297","phase-2-hrs-4642-with-nimotuzumab-and-chemotherapy-for-first-line-treatment-of-advanced-pancreatic-cancer-patients-100575297","NCT06770452","HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","A Single-arm Phase II Study of HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients With KRAS G12D Mutations","Inclusion Criteria:\n\n1.Age: 18-75 (including 18 and 75); 2.Metastatic pancreatic cancer (from pancreatic ductal epithelium) for Arm A; Locally advanced pancreatic cancer (from pancreatic ductal epithelium) for Arm B; 3.Tumor tissue contains KRAS G12D mutation; 4.No systemic antitumor therapy in advanced stage; if previous neoadjuvant \u002F adjuvant therapy, last treatment should be over 6 months; 5.At least one measurable lesion according to the RECIST v1.1 criteria; 6.The ECOG (Eastern Cooperative Oncology) score was 0-1; 7.Expected survival period of 3 months; 8.The functions of vital organs meets the following requirements (any blood components, cell growth factors are not allowed 2 weeks prior to enrollment):\n\n1. Neutrophil count≥1.5×10\\^9 \u002F L;\n2. Platelet≥100×10\\^9 \u002F L;\n3. Hemoglobin≥100 g \u002F L;\n4. Serum albumin≥30 g \u002F L;\n5. Total bilirubin≤1.5×ULN; ALT, AST≤3×ULN and ALP≤2.5×ULN; if the patient has liver metastasis, ALT, ALT and AST≤5×ULN; if the patient has liver or bone metastasis, ALP≤5×ULN;\n6. Creatinine clearance≥50 mL\u002Fmin or serum creatinine ≤1.5×ULN;\n7. Urinary protein \\\u003C2+; if urine protein≥2+, an additional 24 hours urine protein quantification should be tested, and if 24 hours urine protein quantification \\\u003C1g can be enrolled;\n8. ECG: QTcF≤450 ms (male), QTcF≤470 ms (female);\n9. Cardiac color ultrasound: LVEF (left ventricular ejection fraction) ≥50%; 9.Women of childbearing age must have a blood pregnancy test within 7 days before enrollment, the result should be negative and must be non-lactating and should be willing to use appropriate contraception during the trial and within 6 months of treatment. For men, surgical sterilization or consent to use appropriate contraception during the study and within 6 months after completion of treatment.\n\n10.Volunteer to participate in the study and sign the informed consent form, good compliance, agreed to cooperate with the follow-up.\n\nExclusion Criteria:\n\n1.Previous treatment:\n\n1. Previous treatment of targeted therapy against KRAS G12D.\n2. Previous targeted therapy against EGFR.\n3. Received major surgery or major trauma within 4 weeks before enrollment, or palliative local treatment (including but not limited to palliative radiotherapy, interventional therapy) within 2 weeks prior to enrollment.\n4. Have received any other clinical study medication within 4 weeks before enrollment, except for an observational (non-interventional) clinical study or interventional clinical study follow-up.\n\n(5)14 days before enrollment with drugs that strongly inhibit or induce the hepatic drug-metabolizing enzymes CYP3A4 or CYP2C8.\n\n2.The presence of a central nervous system (CNS) metastases. 3.Acute or chronic pancreatitis requiring clinical intervention. 4.Symptoms and signs of gastrointestinal obstruction or obstruction within 6 months before initiation of study treatment but can be screened if surgery is performed and the obstruction is completely resolved.\n\n5.Within 2 weeks prior to enrollment, there is a third space effusion (such as a large amount of pleural fluid, ascites, etc.) that can not reach the stable state (no intervention treatment is needed after the removal of the drainage tube), and only a small amount of effusion on imaging and without clinical symptoms can be enrolled.\n\n6.Severe infection occurred within 4 weeks before enrollment, such as severe pneumonia, bacteremia, infectious complications, requiring hospitalization; fever of unknown cause\\> 38.5℃ within 2 weeks before enrollment (fever caused by the tumor according to the investigator); 2 weeks of enrollment (except in cases of prophylactic antibiotics).\n\n7.Severe cardiovascular and cerebrovascular disease. 8.Patients with known or suspected interstitial pneumonia except only interstitial changes on imaging.\n\n9.Prior history of clear neurological or psychiatric disorders, including epilepsy and dementia.\n\n10.Presence of non-healing wounds (severe, non-healing or split), uncured fractures.\n\n11.Adverse events due to prior treatment prior to enrollment did not return to NCI-CTCAE level 1 (except for alopecia and enrollment criteria; except AEs not affecting the study medication).\n\n12.Malignant tumors other than the primary tumor within the 5 years before enrollment, except those with low risk of metastasis and death: adequately treated cervical carcinoma in situ, skin basal cells or squamous cell carcinoma, etc.\n\n13.Combined with active hepatitis B (hepatitis B surface antigen positive and HBV DNA 500 IU \u002F mL), hepatitis C (hepatitis C antibody positive, and HCV-RNA above the lower limit of detection of the analytical method). Those known to have acquired immunodeficiency syndrome or test positive for HIV, and those infected with active syphilis. Subjects with active tuberculosis or a history of active tuberculosis infection within 48 weeks before screening, with or without treatment.\n\n14.Known to be allergic to any component of HRS-4642; allergic to any component of nytuzumab or other monoclonal antibody \u002F fusion proteins, albumin paclitaxel, gemcitabine.\n\n15.By the investigator, the patient had other factors that might affect the study results or lead to the forced termination of the study.",{"count":341,"type":22},133,[25],"This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.",[345],"Metastatic Pancreatic Carcinoma","2026-06-01",{"date":348,"type":41},"2026-06-03",{"date":350,"type":41},"2025-03-25",{"date":352,"type":22},"2028-02-01",{"name":47,"class":48},2,{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":362,"minAge":18,"maxAge":114,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":371,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":137},"100640577","effects-of-rectal-indomethacin-suppository-on-postoperative-crbd-in-patients-undergoing-lrp-100640577","NCT07607990","Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP","Effects of Rectal Indomethacin Suppository on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Laparoscopic Radical Prostatectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 80 years old (inclusive);\n2. American Society of Anesthesiologists (ASA) physical status classification Class I-III;\n3. Undergoing elective laparoscopic radical prostatectomy under general anesthesia;\n4. Having a clear understanding of the study, voluntarily participating, and providing informed consent signed by themselves or their family members.\n\nExclusion Criteria:\n\n1. Pre-existing bladder diseases, such as overactive bladder (frequency of micturition \\> 3 times per night or \\> 8 times within 24 hours), neurogenic bladder, and bladder outlet obstruction;\n2. Postoperative status of pelvic organs or spine that affects bladder function;\n3. Postoperative status of total proctocolectomy;\n4. Severe cardiac insufficiency (activity tolerance \\\u003C 4 METs) or clearly diagnosed coronary heart disease;\n5. Clearly diagnosed chronic obstructive pulmonary disease (COPD) or a history of asthma;\n6. Hepatic insufficiency with Child-Pugh Class C;\n7. Chronic kidney disease requiring dialysis;\n8. Active peptic ulcer\u002Fhemorrhagic disease;\n9. Body mass index (BMI) ≤ 18 kg\u002Fm² or ≥ 28 kg\u002Fm²;\n10. Chronic analgesic abuse;\n11. Use of other nonsteroidal anti-inflammatory drugs (NSAIDs) within one week;\n12. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs);\n13. Mental or neurological disorders that prevent the completion of rating scales; or cognitive impairment resulting in the loss of capacity for civil conduct.","MALE",{"count":364,"type":22},130,[60],"The postoperative incidence of catheter-related bladder discomfort (CRBD) ranges from 47% to 95%. It increases postoperative pain and agitation, thus requiring early intervention. Although a variety of drugs are used for the prevention or treatment of CRBD, the adverse reactions of most of these drugs have limited their clinical application. In long-term clinical practice, we found that indomethacin suppository has a good therapeutic effect on the discomfort of pelvic-related organs caused by nociceptive stimulation. However, its preventive effect on CRBD has not been reported yet. We hypothesized that indomethacin suppository has a preventive effect on postoperative CRBD. To verify this hypothesis, patients undergoing laparoscopic radical prostatectomy were enrolled in the study. Patients in the intervention group received 50 mg of indomethacin suppository via the rectal route immediately after surgery, while those in the control group received no treatment. The severity of CRBD, pain scores, consumption of analgesics, other perioperative adverse reactions, and patient satisfaction were observed and recorded at 0, 1, 2, and 6 hours after surgery.",[368,369,370],"Prostate Cancer (Post Prostatectomy)","Perioperative Anesthetic","Catheter-related Bladder Discomfort (CRBD)",[372,373,374],"catheter-related bladder discomfort","CRBD","radical prostatectomy","2026-05-25",{"date":377,"type":41},"2026-05-27",{"date":379,"type":41},"2026-01-01",{"date":381,"type":22},"2026-12-31",{"name":47,"class":48},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":395,"conditions":396,"keywords":402,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":137},"100588144","early-phase-1-cdh17-car-t-therapy-in-advanced-malignant-solid-tumors-100588144","NCT06937567","CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors","Exploratory Study on the Safety and Preliminary Efficacy of UCLH80-1 Cells in Patients With CDH17-Positive Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n* Histopathologically confirmed malignant solid tumors, including but not limited to colorectal cancer, gastric cancer, pancreatic cancer, and biliary tract tumors.\n* Patients must have failed standard treatments, be intolerant to standard treatments, or lack effective treatment options.\n* At least one measurable lesion as defined by RECIST v1.1 criteria.\n* Tumor tissue must be available either from prior tumor biopsy or by providing new tumor specimens.\n* Tumor specimens must be confirmed as CDH17-positive by immunohistochemistry (IHC) or immunocytochemistry (ICC) staining.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Expected survival time ≥ 3 months.\n* Appropriate organ function: hematological: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹\u002FL. Hemoglobin (HGB) ≥ 80 g\u002FL; Platelet count (PLT) ≥ 75 × 10⁹\u002FL. Liver Function: aspartate aminotransferase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) ≤ 3.0 × ULN (≤ 5.0 × ULN for patients with primary liver tumors or liver metastases); total bilirubin ≤ 1.5 × ULN (≤ 3.0 × ULN for patients with primary liver tumors or liver metastases; ≤ 3 × ULN for Gilbert's syndrome with direct bilirubin ≤ 1.5 × ULN). Coagulation: international normalized ratio (INR) ≤ 1.5 × ULN (unless on therapeutic anticoagulants); activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (unless on therapeutic anticoagulants). Renal Function: serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance rate ≥ 60 mL\u002Fmin (based on Cockcroft-Gault formula). Cardiac Function: left ventricular ejection fraction (LVEF) ≥ 50% (confirmed by echocardiography). Pulmonary Function: resting oxygen saturation (SpO₂) \\> 92% without supplemental oxygen.\n* Female participants of childbearing potential must have a negative pregnancy test.\n* Female participants of childbearing potential or male participants with partners of childbearing potential must agree to use effective contraception during the study and for 1 year after the final cell infusion.\n* Willingness to sign the informed consent form, demonstrating understanding of the study and agreement to comply with study procedures.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding.\n* Positive hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) with peripheral HBV DNA levels above the lower limit of detection.\n* Positive hepatitis C virus (HCV) antibody with peripheral HCV RNA levels above the lower limit of detection.\n* Positive HIV antibody.\n* Positive syphilis-specific and non-specific antibody tests.\n* Non-hematological toxicity from prior treatment (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has not resolved to ≤ CTCAE grade 1 (except for hair loss and peripheral sensory neuropathy).\n* Prior allogeneic tissue or organ transplant (including bone marrow, stem cell, liver, kidney, etc.), except for transplants not requiring immunosuppression (e.g., corneal or hair transplantation).\n* Patients who have previously received CDH17 CAR-T therapy, except those who received CAR-T infusion within this study.\n* Underwent major surgery within 4 weeks prior to signing informed consent and has not fully recovered, or has a history of serious unresolved trauma.\n* Known central nervous system (CNS) metastases (with exceptions for asymptomatic brain metastases or stable clinical symptoms).\n* Severe active infections or pulmonary diseases requiring systemic corticosteroid treatment within 6 months prior to signing informed consent.\n* Symptomatic congestive heart failure (NYHA class II-IV), severe aortic stenosis, or symptomatic mitral stenosis.\n* ECG showing QTc \\> 450 ms or QTc \\> 480 ms with bundle branch block.\n* Uncontrolled hypertension (SBP ≥ 160 mmHg and\u002For DBP ≥ 100 mmHg).\n* Cerebrovascular accidents within 6 months prior to signing informed consent.\n* Active, chronic, or recurrent severe autoimmune diseases requiring immunosuppressive treatment (with exceptions).\n* Any form of primary or secondary immunodeficiency.\n* Risk of organ perforation or bleeding as judged by the investigator.\n* Severe systemic hypersensitivity reactions to study drugs\u002Fcomponents. - Received live attenuated vaccines within 4 weeks prior to signing informed consent.\n* Participated in another clinical study within 4 weeks prior to signing informed consent.\n* History of another malignancy within the past 5 years, except for adequately treated non-melanoma skin cancer or in situ cancers.\n* Diagnosed with neuropsychiatric disorders or any condition deemed by the investigator as unsuitable for participation.","70 Years",{"count":392,"type":22},36,[394],"EARLY_PHASE1","The investigational product used in this study, UCLH801 cells, is a CAR-T cell therapy specifically targeting CDH17. The proposed indication includes CDH17-positive advanced solid tumors, such as but not limited to colorectal cancer, gastric cancer, pancreatic cancer, biliary tract tumors, neuroendocrine tumors, ovarian cancer, and lung cancer. The primary objective of this study is to evaluate the safety and tolerability of UCLH801 cells in patients with CDH17-positive advanced malignant solid tumors. The secondary objectives include assessing the preliminary efficacy of UCLH801 cells, their pharmacokinetics and pharmacodynamics in the body, and their immunogenicity.\n\nThis study aims to observe how the infusion of UCLH801 cells affects patients 's body, including any discomfort or changes in laboratory test results. Additionally, it will evaluate whether UCLH801 cells have any effect on tumor. Furthermore, the study will investigate how UCLH801 cells are metabolized; the mechanisms through which they exert their effects, and how to develops any immune response or rejection against UCLH801 cells.",[397,398,399,400,401],"Biliary Tract Cancer","Colorectal Carcinoma","Gastric Cancer, Metastatic","Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)","Multiple Cancer",[403,404],"CAR-T","CDH17","2026-05-20",{"date":407,"type":41},"2026-05-26",{"date":409,"type":41},"2024-12-26",{"date":411,"type":22},"2028-05-30",{"name":47,"class":48},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":423,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":433,"leadSponsor":435,"locationsCount":436},"100638397","multimodal-thermal-therapy-with-targeted-and-immunotherapy-for-untreated-unresectable-hcc-100638397","NCT07596134","Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC","Multimodal Thermal Therapy With Targeted Therapy and Immunotherapy Versus Targeted Therapy and Immunotherapy Alone for Systemically Untreated Unresectable (HCC): a Prospective, Multicenter, Open-label, Randomized Controlled Trial.","HLP1-1331","Inclusion Criteria:\n\n* • Age 18-80, regardless of gender;\n\n  * Diagnosed with unresectable HCC by imaging or histology, BCLC stage B or C;\n  * No prior systemic immunotherapy, chemotherapy, targeted therapy, or other systemic drug treatments for HCC;\n  * Presence of an image-evaluable lesion intended for ablation without prior local ablation therapy, with the maximum diameter of the target tumor ≤5 cm;\n  * Child-Pugh score ≤7;\n  * ECOG-PS score of 0-1.\n\nExclusion Criteria:\n\n* • Invasion of the main portal vein;\n\n  * Diffuse hepatocellular carcinoma;\n  * Patients with a history or current diagnosis of brain metastases whose symptoms are not fully controlled (i.e., persistent or worsening symptoms, or requiring adjustments to symptomatic treatment to maintain symptom relief);\n  * Extensive distant metastasis confirmed by imaging (e.g., chest\u002Fabdominal CT\u002FMRI, whole-body bone scan, PET-CT, etc.), including but not limited to diffuse lung metastasis, multiple bone metastases, extensive abdominal\u002Fperitoneal metastasis, or other multi-organ metastases, where the investigator assesses that the extent of metastasis may compromise the safe administration of study treatment or affect efficacy and safety evaluations;\n  * Prior local therapy with the last treatment administered less than 4 weeks before enrollment;\n  * Involvement of major blood vessels such as the hepatic vein or inferior vena cava;\n  * Uncontrolled active infection;\n  * Renal dysfunction with serum creatinine \\>176.8 μmol\u002FL or creatinine clearance \\\u003C30 mL\u002Fmin;\n  * Uncorrectable coagulation abnormalities: platelets \\\u003C50×10⁹\u002FL, prothrombin time \\>18 seconds, prothrombin activity \\\u003C40%, and uncorrectable;\n  * History of esophageal or gastric variceal bleeding without effective treatment via endoscopy, intervention, or surgery;\n  * Patients with active psychiatric disorders;\n  * Patients receiving or requiring systemic glucocorticoids (e.g., prednisone, dexamethasone) at a dose ≥10 mg\u002Fday (prednisone equivalent) or other immunosuppressive drugs (e.g., cyclosporine, tacrolimus, methotrexate) within 14 days prior to enrollment; topical, inhaled, or ophthalmic glucocorticoid use that does not affect systemic immune function may be allowed at the investigator's discretion;\n  * History or current diagnosis of malignancies other than the target tumor in this study (excluding cured low-grade malignancies such as basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ). For low-grade malignancies, eligibility will be determined by the investigator;\n  * Pregnant or breastfeeding women, or women of childbearing potential planning pregnancy during the study or within 3 months after treatment completion;\n  * Expected survival \\\u003C3 months;\n  * Patients deemed unsuitable for participation by the investigator.",{"count":422,"type":22},166,[60],"Multimodal Thermal Therapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone for systemically untreated unresectable hepatocellular carcinoma (HCC)",[426],"Unresectable Hepatocellular Carcinoma (HCC)",[428],"HCC","2026-05-19",{"date":431,"type":41},"2026-05-22",{"date":375,"type":22},{"date":434,"type":22},"2029-05-25",{"name":47,"class":48},4,{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":454,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":137},"100637505","phase-2-neoadjuvant-treatment-of-fulzerasib-plus-cetuximab-n01-in-kras-g12c-mutated-locally-advanced-colorectal-cancer-with-or-without-resectable-metastases-100637505","NCT07581912","Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases","FALCO","Inclusion Criteria:\n\n* The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;\n* Age: 18-80 years old, PS score 0-1;\n* Colorectal adenocarcinoma diagnosed by histopathology, preoperative staging: T4N0-2M0, T3N2M0, T0-4N0-2M1a (with metastatic lesions present, requiring MDT evaluation as resectable); PMMR\u002FMSS, KRAS G12C mutation, and both NRAS and BRAF wild-type\n* Locally advanced colorectal cancer requires initial diagnosis of patients who have not received systematic treatment in the past. Patients with resectable metastatic lesions are required to have not received targeted therapy in the past, and new metastases after adjuvant therapy can be included in this study.\n* The main organ functions well and meets the following criteria:\n\n  1. Blood routine examination criteria (corrected for no blood transfusion or use of hematopoietic stimulating factor drugs within 7 days before screening): hemoglobin (HGB) ≥ 90g\u002FL (if chronic anemia is caused by chronic blood loss from the tumor and the researcher evaluates the stability of vital signs, it can be included in the group); absolute neutrophil count (NEUT) ≥ 1.5 × 109\u002FL; platelet count (PLT) ≥ 75 × 109\u002FL;\n  2. Biochemical tests must meet the following standards: total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN) (Gilbert syndrome subjects, ≤ 3 × ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN; serum creatinine (CR) ≤ 1.5ULN or creatinine clearance rate (CCR) ≥ 50ml\u002Fmin.\n  3. Coagulation or thyroid function tests must meet the following criteria: prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR) ≤ 1.5 × ULN (without anticoagulant therapy); thyroid stimulating hormone (TSH) ≤ ULN; If there are abnormalities, T3 and T4 levels should be examined (if there is no T3 in the center, T4 can be replaced by FT3 and FT4), and if the level is normal, it can be selected.\n* Cardiac ultrasound evaluation: Left ventricular ejection fraction (LVEF) ≥ 50%.\n\nExclusion Criteria:\n\nThose who meet any of the following criteria will not be included in this trial:\n\n* Patients with MSI-H\u002FdMMR present;\n* Patients with multiple metastases that cannot be resected;\n* Combined diseases and medical history:\n\n  1. Has had or is currently suffering from other malignant tumors within the past 3 years. The following situations can be included in the group:\n\n     Cured cervical carcinoma in situ, non melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basement membrane)\\];\n  2. Patients with active inflammatory bowel disease within the first 4 weeks of enrollment;\n  3. Uncontrollable pleural effusion, pericardial effusion, or ascites that require repeated drainage;\n  4. Unrelieved toxic reactions above CTCAE grade 1 caused by any previous anti-tumor treatment (excluding hair loss and ≤ grade 2 neurotoxicity caused by oxaliplatin);\n  5. Within 4 weeks prior to the start of the study, any bleeding events ≥ CTCAE grade 3 occurred in patients with unhealed wounds, ulcers, or fractures;\n  6. History of arterial\u002Fvenous thrombotic events within 6 months, such as cerebrovascular accidents (including transient ischemic attacks, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;\n  7. Individuals with a history of substance abuse involving psychotropic drugs who are unable to quit;\n  8. Subjects with any severe and\u002For uncontrolled diseases, including: uncontrolled hypertension (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg despite standard antihypertensive treatment); myocardial ischemia or myocardial infarction ≥grade 2, arrhythmia (QTc ≥450 ms in males, QTc ≥470 ms in females, and ≥grade 2 congestive heart failure (New York Heart Association (NYHA) classification); active or uncontrolled severe infections (≥CTC AE grade 2 infection); cirrhosis, active hepatitis\\*; (\\*Active hepatitis \\[Hepatitis B reference: HBsAg positive and HBV DNA positive (\\>2500 copies\u002FmL or \\>500 IU\u002FmL); Hepatitis C reference: HCV antibody positive and HCV viral load exceeding the upper limit of normal\\] Note: For subjects meeting enrollment criteria, those with hepatitis B surface antigen positive or hepatitis B core antibody positive, or hepatitis C patients, must receive continuous antiviral treatment to prevent viral activation); renal failure requiring hemodialysis or peritoneal dialysis; history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or organ transplantation history; poorly controlled diabetes (fasting blood glucose (FBG) \\>10 mmol\u002FL); urinalysis indicating proteinuria ≥++, and confirmed 24-hour urine protein quantification \\>1.0g; a history of confirmed neurological or psychiatric disorders requiring treatment, including epilepsy or dementia.\n* Tumor-related symptoms and treatment: Previously received targeted drug therapy (including G12C inhibitors, bevacizumab, etc.);\n* According to the investigator's judgment, subjects with serious diseases that pose a significant risk to their safety or affect the completion of the study, or those deemed ineligible for enrollment due to other reasons.","85 Years",{"count":446,"type":22},40,[25],"Background：KRAS mutations are the most common genetic alterations in colorectal cancer (CRC), associated with aggressive tumor biology and poor prognosis. For metastatic CRC harboring KRAS mutations, first-line standard treatment is chemotherapy plus bevacizumab. However, its anti-angiogenic effects contraindicate perioperative use. KRAS G12C, the first druggable KRAS target, accounts for \\~3% of CRC KRAS mutations. KRAS G12C inhibitor monotherapy shows efficacy in post-standard-therapy metastatic CRC, while combination with RAS-MAPK pathway blockade demonstrates superior efficacy. Based on promising frontline data combining KRAS G12C inhibitors with anti-EGFR antibodies in metastatic CRC, we evaluate neoadjuvant fulzerasib plus cetuximab N01 in locally advanced KRAS G12C-mutated CRC, with or without resectable metastases.\n\nMethods：Single-arm, multicenter, phase II trial (N=40). Eligibility: age 18-80 years, ECOG 0-1, histologically confirmed colorectal adenocarcinoma (stages T4N0-2M0, T3N2M0, T0-4N0-2M1a \\[resectable metastases confirmed by multidisciplinary discussion\\]), KRAS G12C mutation, NRAS\u002FBRAF wild-type, pMMR\u002FMSS. Neoadjuvant therapy: fulzerasib (qd, po, d1-28) plus cetuximab N01 (500 mg\u002Fm², IV, q2w) for 2 months. Safety assessments (CBC, liver\u002Frenal function, QoL) every 2 weeks; CEA monthly. Tumor response assessed by CT chest\u002Fabdomen and rectal MRI at 2 months. Radical surgery for responders (cCR patients may choose watchful waiting). Adjuvant therapy per pathological response. Follow-up: CEA every 3 months, CT every 6 months. Primary endpoint: overall response rate (pCR or cCR). Secondary endpoints: ORR, 1-year DFS, 3-year DFS, QoL. RECIST v1.1 for disease assessment; NCI-CTCAE v5.0 for adverse events.\n\nHypothesis：This chemotherapy-free neoadjuvant regimen combining a KRAS G12C inhibitor with cetuximab N01 may enhance perioperative safety and improve prognosis and quality of life in patients with KRAS G12C-mutated CRC.",[450,451,452,453],"Colorectal Cancer","KRAS G12C Mutant Advanced Solid Tumors","Fulzerasib","Cetuximab N01",[455,456,457,458,459],"fulzerasib","cetuximab N01","chemotherapy-free","KRAS G12C mutant","locally advanced colorectal cancer","2026-05-11",{"date":462,"type":41},"2026-05-12",{"date":464,"type":41},"2026-04-30",{"date":466,"type":22},"2031-12",{"name":47,"class":48},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":23,"phases":477,"briefSummary":478,"conditions":479,"keywords":484,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":306},"100616588","high-flow-nasal-cannula-for-preventing-hypoxia-during-sedated-endoscopy-in-high-risk-obstructive-sleep-apnea-patients-100616588","NCT07307560","High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients","High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients: A Multicenter Randomized Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* STOP-Bang score ≥5.\n* Scheduled for sedated gastrointestinal endoscopy (gastroscopy, colonoscopy, or combined gastroscopy + colonoscopy).\n* The estimated duration of the procedure does not exceed 45 minutes.\n* Patients have signed the informed consent form.\n\nExclusion Criteria:\n\n* Coagulation disorders or bleeding tendency (e.g., oral\u002Fnasal bleeding risk, mucosal injury, space-occupying obstructions).\n* Active upper respiratory tract infection (oral, nasal, or pharyngeal), or fever (core temperature \\>37.5°C).\n* Chronic obstructive pulmonary disease or other acute\u002Fchronic pulmonary diseases requiring long-term or intermittent oxygen therapy, or preoperative SpO₂ ≤ 92% on room air.\n* Severe organ dysfunction, including: Cardiac insufficiency (\\\u003C4 METs), Severe renal insufficiency (requiring dialysis), Diagnosed severe hepatic insufficiency, Increased intracranial pressure, ASA physical status ≥ IV.\n* Confirmed pregnancy or current breastfeeding.\n* Known allergy to sedatives (e.g., propofol) or medical adhesives.\n* Multiple traumatic injuries.\n* Current participation in another clinical trial.\n* Other conditions deemed unsuitable by the investigator",{"count":476,"type":22},600,[60],"Hypoxia represents the most frequent adverse event during propofol-sedated gastrointestinal endoscopy. The STOP-BANG questionnaire serves as a widely adopted, straightforward tool for screening obstructive sleep apnea (OSA) risk, with a score ≥5 identifying high-risk OSA patients who are particularly susceptible to hypoxia under sedation. Although preliminary research from our team suggests that High-Flow Nasal Cannula (HFNC) may lower the incidence of hypoxemia, evidence remains limited and inconsistent in studies specifically targeting high-risk OSA populations. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxia during sedated gastrointestinal endoscopy in patients identified as high-risk for OSA.",[480,481,482,483],"Hypoxia","Esophageal Cancer","Gastric Cancer (Diagnosis)","Obstructive Sleep Apnea (OSA)",[485,480,483,486],"Sedation","Gastrointestinal Endoscopy","2026-05-01",{"date":489,"type":41},"2026-05-04",{"date":491,"type":41},"2025-12-21",{"date":493,"type":22},"2026-12-01",{"name":47,"class":48},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":502,"maxAge":503,"enrollmentInfo":504,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":512,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":436},"100636237","effect-of-high-flow-nasal-cannula-oxygen-therapy-on-hypoxemia-in-pediatric-sedated-bronchoscopy-100636237","NCT07563075","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* 1 year ≤ age ≤ 6 years,\n* Weight ≥ 10 kg,\n* Undergoing elective sedated bronchoscopy,\n* Expected procedure duration ≤ 45 minutes,\n* Written informed consent obtained from the subject's legal guardian.\n\nExclusion Criteria:\n\n* preoperative SpO₂ \\\u003C 95% on room air,\n* Already sedated and tracheally intubated,\n* Known history of pneumothorax, known congenital or acquired upper airway abnormalities (e.g., nasopharyngeal structural anomalies), or history of difficult airway,\n* Coagulation disorders or predisposition to oral\u002Fnasal bleeding, mucosal injury, or space-occupying lesions,\n* Severe cardiac insufficiency (\\\u003C 4 METs), severe renal insufficiency (requiring dialysis), diagnosed severe hepatic insufficiency, Increased intracranial pressure, or ASA classification ≥ IV,\n* Allergy to propofol or sufentanil,\n* Multiple traumatic injuries,\n* Current participation in another clinical trial,\n* Other conditions deemed unsuitable by the investigator.","1 Year","6 Years",{"count":505,"type":22},430,[60],"Due to children's lower oxygen reserves and higher oxygen consumption, sedation can easily lead to respiratory adverse events such as hypoxemia. It has been reported that the incidence of hypoxemia during pediatric bronchoscopy is high, highlighting that hypoxemia in pediatric painless bronchoscopy is an urgent problem requiring a solution. High-flow nasal cannula (HFNC) oxygen therapy delivers heated and humidified breathing gas with a precisely controllable oxygen concentration, at flow rates exceeding the patient's peak inspiratory flow, directly via unsealed nasal prongs. It is a simple, comfortable, effective, and non-invasive respiratory support method that has been widely adopted in clinical practice. However, the effectiveness of HFNC in pediatric sedation remains unclear. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxemia during sedated bronchoscopy in pediatric patients.",[509,510,511],"Hypoxemia","Pneumonia","Pulmonary Neoplasm",[513,509,485,514,515],"Bronchoscopy","Pediatric","High-flow nasal cannula","2026-04-28",{"date":487,"type":41},{"date":519,"type":22},"2026-04-01",{"date":521,"type":22},"2027-03-31",{"name":47,"class":48},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":529,"maxAge":19,"enrollmentInfo":530,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":137},"100630417","early-phase-1-safety-and-efficacy-of-metabolically-armed-gpc3-car-t-cells-injection-meta10-gpc3-in-patients-with-unresectable-recurrentmetastatic-hepatocellular-carcinoma-100630417","NCT07487402","Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent\u002FMetastatic Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Age \\>18 years and ≤75 years, male or female.\n* Histologically confirmed recurrent or metastatic hepatocellular carcinoma (HCC) that is not amenable to surgical resection.\n* At least one measurable target lesion according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n* Tumor tissue must test positive for GPC3 expression by immunohistochemical (IHC), defined as \\> 25% of tumor cells staining for GPC3 in the pathological specimen. Preferably, the target lesion sample should be used, including freshly obtained tumor tissue or archival tissue samples deemed acceptable by the investigator.\n* Expected survival ≥ 12 weeks.\n* Child-Pugh class A.\n* Eastern Cooperative Oncology Group (ECOG) performance status was 0-1.\n* For subjects who are HBsAg or HBcAb positive, HBV-DNA must be \\\u003C 2 000 IU\u002FmL; HBsAg-positive patients must receive antiviral therapy according to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition).\n* Adequate venous access for leukapheresis or venous blood collection.\n* Hematologic parameters: WBC ≥ 2.5 × 10⁹\u002FL, platelets ≥ 60 × 10⁹\u002FL, Hb ≥ 9.0 g\u002FdL, lymphocytes ≥ 0.4 × 10⁹\u002FL.\n* Biochemical parameters: Serum albumin ≥ 30 g\u002FL; Lipase and amylase ≤ 1.5 × ULN; serum creatinine ≤ 1.5 × ULN and estimated creatinine clearance ≥ 40 mL\u002Fmin; ALT and AST ≤ 5 × ULN; serum total bilirubin ≤ 2.5 × ULN; prothrombin time ≤ 4s longer above normal.\n* Women or childbearing potential must have a negative serum pregnancy test within 14 days before CAR-T cell infusion and agree to use effective contraception for 12 months after infusion. Male subjects with partners of childbearing potential must having undergone a vasectomy or agree to use reliable contraception during the study period.\n* Ability to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women of childbearing potential who test positive on a pregnancy test during the screening period).\n* Active hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection; seropositivity for Human Immunodeficiency (HIV) or syphilis.\n* Any uncontrolled active infection, including but not limited to active pulmonary tuberculosis.\n* Therapeutic doses of corticosteroids must be discontinued at least 2 weeks prior to Meta10-GPC3 infusion; any immunosuppressive medications must be discontinued at least 4 weeks before signing the informed consent form.\n* History of hypersensitivity to immunotherapy or related agents, β-lactam antibiotics, or other severe allergic reactions.\n* History or presence of hepatic encephalopathy.\n* Clinically significant ascites, defined as ascites detectable on physical examination or requiring therapeutic intervention (excluding ascites detected only by imaging that does not require intervention).\n* Imaging showing that HCC occupies ≥ 50 % of normal liver volume, or presence of tumor thrombus in the main portal vein or inferior vena cava.\n* Clinically significant central-nervous-system (CNS) disorders (excluding subjects with CNS HCC metastases).\n* Active or decompensated cardiac illness (requiring hospitalization or surgical intervention within the past 6 months), or poorly pression ≥ 160\u002F100 mmHg uncontrolled with medication. Stable coronary artery disease or well-controlled hypertension is allowed.\n* Active autoimmune disease requiring immunosuppressive therapy.\n* Prior organ transplantation or currently on an organ transplant waiting list (including but not limited to liver transplantation).\n* Any anti-HCC therapy within 2 weeks prior to leukapheresis or blood collection, including but not limited to surgical resection, interventional therapy, radiotherapy, chemotherapy, or immunotherapy.\n* History or concurrent presence of other malignancies, except for the following: surgically removed non-melanoma skin cancer, cured cervical carcinoma in situ, localized prostate cancer, low-stage bladder cancer, ductal carcinoma in situ of the breast, or any malignancy without recurrence or treatment within the past 2 years.\n* Other severe medical conditions, including but not limit to: poorly controlled diabetes (post-treatment HbA1c \\> 7 %), severe cardiac dysfunction (LVEF \\\u003C 45 %), myocardial infarction, unstable angina, or unstable arrhythmia within 6 months, pulmonary embolism, chronic obstructive pulmonary disease, interstitial lung disease, forced expiratory volume in 1 second (FEV1) \\\u003C 60 %, gastric ulcer, history of gastrointestinal bleeding, documented bleeding diathesis, uncontrolled thrombotic events, major bleeding, or DVT within 12 months prior to informed consent.\n* Active neurological autoimmune or inflammatory disorders (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis).\n* History of QT-interval prolongation or severe cardiac disease.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation in the study (e.g., poor compliance).","19 Years",{"count":531,"type":22},27,[394],"A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent\u002FMetastatic Hepatocellular Carcinoma.",[535],"Hepatocellular Carcinoma (HCC)",[537,538,539],"Meta10-GPC3","unresectable recurrent\u002Fmetastatic hepatocellular carcinoma","IL-10","2026-04-16",{"date":542,"type":41},"2026-04-21",{"date":544,"type":22},"2026-03-30",{"date":546,"type":22},"2029-04-15",{"name":47,"class":48},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":17,"minAge":555,"maxAge":556,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":559,"briefSummary":560,"conditions":561,"keywords":563,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":573},"100599884","china-colorectal-cancer-screening-trial-1-c-cost1-100599884","NCT07090291","China Colorectal Cancer Screening Trial 1 (C-Cost1)","China Colorectal Cancer Screening Trial 1 (C-Cost1): Colonoscopy Versus FIT Versus FIT Plus Blood Test in the Average Risk Population","Inclusion Criteria:\n\n1. Age: 45-74 years old;\n2. In good general condition, with normal mental state and voluntarily signing the informed consent form;\n\nExclusion Criteria:\n\n1. Personal history of colorectal cancer or precancerous lesions;\n2. History of previous colonrectal resection surgery;\n3. Diagnosed with cancer before enrollment or currently receiving any cancer-related treatment;\n4. Having received colonoscopy, flexible sigmoidoscopy, CT colonography and other examinations within the past 5 years;\n5. Having received FIT or FIT-sDNA or cfDNA test within the past 1 year;\n6. Symptomatic lower gastrointestinal diseases or symptoms suggesting the need for diagnostic colonoscopy for confirmation;\n7. Accompanied by severe diseases that are not suitable for colorectal cancer screening;","45 Years","74 Years",{"count":558,"type":22},60300,[60],"Colorectal cancer (CRC) is one of the most common malignancies in China. Currently, its incidence rate is increasing at a rate of 4% per year, exceeding the global annual average growth rate. Screening and early diagnosis of colorectal cancer and precancerous lesions are key measures to reduce the disease burden of colorectal cancer in China. In previous clinical studies, colorectal cancer screening in high risk population received extensive attention. However, it cannot be ignored that the majority of sporadic colorectal cancers occur in the average risk population. Therefore, there is an urgent need to develop new approach for colorectal cancer screening in the average risk population in China.\n\nFecal Immunochemical Testing (FIT) initial screening followed by diagnostic colonoscopy is widely recommended by colorectal cancer screening guidelines worldwide. The current colorectal cancer screening approach faces challenges including limited sensitivity of initial screening technologies and insufficient population coverage in organized screening programs in China. As initial screening technologies, non-invasive blood tests which detects cfDNA methylation have been reported to have higher accuracy than FIT in detecting colorectal cancer. However, There is a lack of randomized controlled trials (RCTs) comparing the effectiveness of colonoscopy, FIT and FIT plus blood test for colorectal cancer screening.\n\nIn China Colorectal Cancer Screening Trial 1 (C-Cost1), we propose to perform a multicenter, cluster randomized, parallel group trial directly comparing colonoscopy with FIT and with FIT plus blood test in the average risk population in China. The main research hypotheses are: (1) The screening protocol of FIT group (Group B) is non-inferior to the colonoscopy group (Group A) in the colorectal cancer mortality rate at 10 years; (2) The screening protocol of FIT plus blood test group (Group C) is non-inferior to the colonoscopy group (Group A) in the colorectal cancer mortality rate at 10 years. Both of the two hypotheses should be met.",[450,562],"Advanced Adenoma",[564],"FIT; FIT plus blood test; cfDNA methylation; Colorectal cancer; Advanced colorectal adenoma; Early screening; Average risk population","2026-04-12",{"date":567,"type":41},"2026-04-14",{"date":569,"type":41},"2025-08-08",{"date":571,"type":22},"2035-07",{"name":47,"class":48},7,{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":137},"100413241","phase-2-cd19-car-t-therapy-for-patients-with-newly-diagnosed-high-risk-large-b-cell-lymphoma-100413241","NCT04661020","CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma","Clinical Trial for the Efficacy and Safety of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma","Inclusion Criteria:\n\n1. Age no less than 18, no gender limit;\n2. Newly diagnosed high-risk Large B-cell Lymphoma, which was defined by the following criteria: (1) DLBCL not otherwise specified with an IPI score ≥3 at diagnosis, (2) high grade B-cell lymphoma (HGBL) with gene rearrangement of MYC and BCL2 and\u002For BCL6, (3) HGBL not otherwise specified;\n3. Confirmed CD19 and CD20 postive expressions in lymphoma cells\n4. ECOG score 0-2;\n5. Total bilirubin ≤ 51 umol\u002FL, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol\u002FL;\n6. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;\n7. No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;\n8. Estimated survival time ≥ 3 months;\n9. Patients or their legal guardians volunteer to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Central nervous system involvement by lymphoma；History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;\n2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;\n3. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);\n4. Active infection of hepatitis B virus or hepatitis C virus;\n5. Previously treated with any CAR-T cell product or other genetically modified T cell therapies;\n6. Insufficient amplification capacity in response to CD3\u002FCD28 co-stimulus signal (\\\u003C5 times) ;\n7. Other uncontrolled diseases that were not suitable for this trial;\n8. Patients with HIV infection;\n9. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.",{"count":446,"type":22},[25],"A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma",[585],"Large B-Cell Lymphoma (LBCL)",[587,588,403],"CD19","Large B-Cell Lymphoma",{"date":590,"type":41},"2026-04-07",{"date":592,"type":41},"2020-12-03",{"date":594,"type":22},"2026-12-20",{"name":47,"class":48},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":603,"minAge":18,"maxAge":604,"enrollmentInfo":605,"targetDuration":4,"studyType":23,"phases":607,"briefSummary":608,"conditions":609,"keywords":613,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":137},"100629908","teas-combined-with-triple-antiemetic-drugs-to-prevent-ponv-in-high-risk-patients-100629908","NCT07480785","TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients","Transcutaneous Electrical Acupoint Stimulation Combined With Triple Antiemetic Drugs for Postoperative Nausea and Vomiting in High-Risk Patients: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Women scheduled for laparoscopic surgery ；\n* Aged 18-65 years；\n* ASA Class I-III；\n* Apfel score ≥ 3 (female sex, non-smoker, history of PONV and\u002For motion sickness).\n\nExclusion Criteria:\n\n* Patients with a history of allergy to the investigational drug or contraindications；\n* Long-QT syndrome ；\n* Pregnancy, lactation, or menstruation ；\n* Current smoker；\n* Nausea\u002Fvomiting or use of antiemetics, opioids, or systemic corticosteroids within 24 h before surgery；\n* Requirement for post-operative sedation and mechanical ventilation ；\n* Severe renal or hepatic impairment ；\n* Psychiatric or neurological disorder ；\n* Vertebrobasilar insufficiency；\n* Vestibular disease；\n* Language or communication barrier ；\n* Skin lesion or infection at the acupoint stimulation site ；\n* Upper-limb nerve injury ；\n* Implanted cardiac pacemaker or defibrillator ；\n* Participation in another clinical trial within the past 4 weeks.","FEMALE","65 Years",{"count":606,"type":22},780,[60],"The goal of this clinical trial is to evaluate the effects of transcutaneous electrical acupoint stimulation (TEAS) combined with triple antiemetics for postoperative nausea and vomiting (PONV) in high-risk patients.\n\nThe primary question it seeks to answer is:\n\nDoes TEAS combined with triple antiemetics further reduce the incidence of PONV in high-risk subjects? Researchers will compare active TEAS with sham stimulation to determine whether the addition of TEAS to dexamethasone, palonosetron, and droperidol lowers the PONV rate beyond that achieved by the triple-drug prophylaxis alone.",[610,611,612],"Uterine Fibroids (Leiomyoma)","Ovarian Tumors","Gallstones",[614,615,616],"postoperative nausea and vomiting","transcutaneous electrical acupoint stimulation","high-risk patients with PONV","2026-03-15",{"date":619,"type":41},"2026-03-18",{"date":621,"type":41},"2026-01-16",{"date":623,"type":22},"2027-10-31",{"name":47,"class":48},{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":17,"minAge":631,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":23,"phases":634,"briefSummary":635,"conditions":636,"keywords":640,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":137},"100629851","a-phase-ii-clinical-two-stage-study-of-transcranial-magnetic-stimulation-in-preventing-postoperative-delirium-in-elderly-patients-after-urological-surgery-100629851","NCT07480044","A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery","Inclusion Criteria:(1) Age ≥ 60 years old; (2) Patients scheduled for elective urological surgery under general anesthesia with tracheal intubation; (3) ASA classification I - III; (4) Estimated operation duration ≥ 2 hours; (5) Informed consent from the patient or their guardian; (6) Proficient in communicating in Chinese. -\n\nExclusion Criteria:(1) Patients with permanent lack of autonomy (2) Not applicable for delirium assessment: including language disorders, deafness, blindness or aphasia, coma (3) With treatment abandonment or brain death (4) Known pregnancy or lactation (5) Unable to obtain consent according to national regulations (6) Patients forcibly hospitalized by regulatory authorities (compulsory measures) (7) With cardiac pacemaker or stent implantation (8) Patients with delirium (9) Patients with known brain lesions (10) Patients with known epilepsy history, having taken drugs that can cause epileptic seizures, having metal implants in the neck or brain, or having cerebral hemorrhage ，Acute phase, acute infectious diseases (11) Habitual treatment with antipsychotic drugs (12) Received antipsychotic drug treatment in the ICU before enrollment (13) Patients with severe liver dysfunction (Child-Pugh C grade) (14) Patients with severe kidney dysfunction (requiring dialysis before surgery) (15) Severe heart failure (METS \\\u003C 4) (16) Preoperative cognitive impairment as determined by a MoCA evaluation prior to surgery;\n\n\\-","60 Years",{"count":633,"type":22},220,[60],"Cases were included based on the inclusion and exclusion criteria, and induction, maintenance, and recovery were conducted in accordance with the standard protocol for general anesthesia. After tracheal intubation and before tracheal tube removal at the end of the surgery, the parameters for iTBS stimulation frequency and duration were as follows: intensity was 80% of the active movement threshold, with 3 pulses per cluster at 50Hz, a frequency of 5Hz, 30 clusters of 10 pulses each, an 8 - second interval, and a single 600 - pulse; the 8 - shaped coil was connected to the electrodes in the designated head area (left frontal lobe cortex).Observation contents: Whether there is postoperative delirium and its severity: 3D - CAM assessment scale, DMAS assessment scale; awakening time, extubation time, PACU stay time, hospital stay time; 1 - 7 days after surgery or before discharge, POD assessment and pain - sleep assessment, the first time getting out of bed; postoperative complications; adverse reactions; adverse events, and so on.",[637,638,639],"Postoperative Delirium (POD)","Prostate Cancer","Kidney Tumor",[641,642,643],"Transcranial Magnetic Stimulation Device","elderly patients","Postoperative Delirium","2026-03-13",{"date":619,"type":41},{"date":647,"type":22},"2026-03-20",{"date":649,"type":22},"2028-12-01",{"name":47,"class":48},{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":23,"phases":658,"briefSummary":659,"conditions":660,"keywords":662,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":137},"100570738","early-phase-1-safety-and-efficacy-of-metabolically-armed-cd19-car-t-cells-meta10-19-in-the-treatment-of-moderate-to-severe-active-sle-clinical-research-100570738","NCT06711146","Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research","Inclusion Criteria:\n\n* All subjects or guardians must sign an informed consent form approved by the Ethics Committee in person before commencing any screening process;\n* Be over 18 years of age, male or female;\n* A diagnosis of SLE according to the 2012 systemic lupus international collaborating clinics(SLICC);\n* The history of SLE prior to screening was at least 6 months, and the disease remained active at least 2 months after the use of a stable standard SLE regimen prior to screening:\n\n  1. Conventional regimens for SLE are corticosteroids and one or more immunomodulatory drugs over 6 months；\n  2. Oral corticosteroids must meet the following requirements:\n\n     * Prednisone (or equivalent) ≥7.5 mg\u002F day, and ≤60 mg\u002F day；\n     * There is no minimum daily dose requirement for corticosteroids when used in combination with immunosuppressants；\n     * At least 8 weeks of treatment prior to screening, and the dose must be kept stable for \\> 2 weeks.\n* Screening is positive for antinuclear antibodies, and\u002For anti-DS-DNA antibodies, and\u002For anti-Smith antibodies；\n* SELENA-SLEDAI score ≥8 during the screening period. Score ≥6 for SELENA-SLEDAI clinical symptoms (except for low complement and\u002For anti-DS-DNA antibodies) if low complement and\u002For anti-DS-DNA antibody score is present；\n* Women of childbearing age and all male patients must consent to use a effective contraception for at least 12 months after Meta10-19 infusion and until two consecutive PCR tests show no more CAR T cells in vivo;\n* CD19 expression was positive by or flow cytometry ;\n* Organ function：\n\n  1. Complete blood count (CBC) test \\[the following criteria should be met within 24 hours prior to apheresis, and supportive treatment such as transfusion, platelet transfusion, cell growth factor (except recombinant erythropoietin) should be avoided within 7 days prior to detection\\]\n\n     * Lymphocyte count ≥ 0.5×109\u002FL (except for those receiving bridging chemotherapy);\n     * Platelet count ≥ 25×109\u002FL;\n     * Hemoglobin ≥ 70.0 g\u002FL\n  2. Blood Biochemistry:\n\n     * Serum creatinine (Scr) ≤ 1.5 x ULN, or\n     * endogenous creatinine clearance ≥ 40 mL\u002Fmin (using Cockcroft-Gault formula);\n     * alanine aminotransferase (ALT) ≤ 2.5 x ULN;\n     * aspartate aminotransferase (AST) ≤ 2.5 ×ULN;\n     * Total bilirubin (TBIL) ≤ 2 ×ULN; Subjects with total bilirubin \\\u003C 3 × ULN and direct bilirubin \\\u003C 1.5× ULN with Gilbert-.Meulengracht syndrome could be included;\n     * Serum lipase and amylase ≤ 1.5×ULN;\n     * Alkaline phosphatase (ALP) ≤ 2.5 ×ULN;\n     * In case of bone or liver metastasis, AST, ALT and ALP ≤ 5 ×ULN;\n     * Prothrombin time (PT) extended ≤ 4 s, fibrinogen ≥ 1 g\u002FL, activated partial thromboplastin time (APTT) ≤ 1.5 ×ULN;\n  3. Pulmonary function: ≤CTCAE grade 1 dyspnea and oxygen saturation of blood (SaO2) \\> 91% in indoor air environment..\n* Hemodynamic stability was determined by echocardiography or multichannel radionuclide angiography (MUGA) and LVEF ≥45％.\n\nExclusion Criteria:\n\n* Severe lupus nephritis (defined as proteinuria \\> 6 g\u002F24h or serum creatinine \\> 2.5 mg\u002FdL or 221 μmol\u002FL), treatment with active nephritis with Prohibited drugs, hemodialysis, or prednisone ≥100 within 8 weeks prior to screening mg\u002Fd or equivalent glucocorticoid therapy ≥14 days.\n* Prior to screening, other lupus crises, such as active central nervous system lupus, severe hemolytic anemia, severe thrombocytopenic purpura, severe agranulocytosis, severe myocardial damage, severe lupus pneumonia or pulmonary hemorrhage, severe lupus hepatitis, and severe vasculitis.\n* Clinically significant central nervous system diseases or pathological changes not caused by lupus prior to screening, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, convulsions\u002Fconvulsions, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.\n* Combined with other autoimmune diseases, systematic treatment is needed.\n* History of major organ transplantation (e.g., heart, lung, kidney, liver) or hematopoietic stem cell\u002Fbone marrow transplantation.\n* IgA deficiency was present during screening (serum IgA level \\\u003C 10 mg\u002FdL).\n* Other conditions that the investigator considered should not be enrolled in this clinical study.",{"count":392,"type":22},[394],"A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Moderate to Severe Active Systemic Lupus Erythematosus",[661],"Systemic Lupus Erythematosus",[663,664,661],"Meta10-19","CAR-T Cells Therapy","2026-03-10",{"date":644,"type":41},{"date":668,"type":41},"2024-12-24",{"date":670,"type":22},"2027-04-05",{"name":47,"class":48},""]